Study Casts Doubt on the Use of Immunoglobulin Replacement Therapy for CLL

A new study has revealed that in patients with chronic lymphocytic leukemia (CLL), treatment with immunoglobulin ...

AUGUST 18, 2025

Statins May Improve Survival in Patients With CLL or SLL

A new study adds to the growing evidence that statins may have an anti-cancer effect. 

APRIL 23, 2025

Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In patients who received prior chronic lymphocytic leukemia/small lymphocytic lymphoma-directed therapy but require ...

MARCH 10, 2025

Novel Therapy Shows Impressive Activity in Heavily Pretreated CLL

As an alternative to the targeted therapies now commonly used in relapsed/refractory (R/R) chronic lymphocytic ...

FEBRUARY 24, 2025

Paving the Way for First-Line Oral Doublet in CLL

An all-oral combination of the BTK inhibitor acalabrutinib (Calquence, AstraZeneca) and the BCL-2 inhibitor ...

JANUARY 29, 2025

Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by the accumulation of circulating ...

APRIL 10, 2024

Breyanzi Approved for Adults With Relapsed/Refractory CLL or SLL

The FDA granted accelerated approval of lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), a CD19-directed ...

MARCH 19, 2024

Measurable Residual Disease Testing in the Community Oncology Setting

In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...

FEBRUARY 7, 2024

Using MRD to Determine Duration of Targeted Therapy Improves Outcomes in CLL

Overall survival (OS) can be improved in fit patients with chronic lymphocytic leukemia (CLL) if the minimal ...

JANUARY 12, 2024

FDA Grants Accelerated Approval to Jaypirca for CLL and SLL

The FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly) for adults with chronic lymphocytic ...

DECEMBER 4, 2023

Nemtabrutinib Shows Promise for Relapsed CLL and NHL

The Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib (Merck) may offer a new treatment option for ...

NOVEMBER 21, 2023

New-Generation BTK Inhibitor Found Safer, More Effective for CLL and SLL

Relative to ibrutinib, the second-generation Bruton tyrosine kinase inhibitor zanubrutinib was more effective and ...

JANUARY 16, 2023